基于RBD抗原性的五种SARS-CoV-2血清型分类  

Classification of five SARS-CoV-2 serotypes based on RBD antigenicities

作　　者：胡世雄 吴春丽 吴鑫凯 马雪慧 舒畅 陈茜 郑安琪 杨惠婷 陆剑 杜沛 高福 王奇慧 Shixiong Hu;Chunli Wu;Xinkai Wu;Xuehui Ma;Chang Shu;Qian Chen;Anqi Zheng;Huiting Yang;Jian Lu;Pei Du;George Fu Gao;Qihui Wang(College of Veterinary Medicine,Shanxi Agricultural University,Jinzhong 030801,China;CAS Key Laboratory of Pathogen Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China;School of Life Sciences,Yunnan University,Kunming 650091,China;School of Life Sciences,Peking University,Beijing 100871,China;State Key Laboratory of Microbial Resources,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China;Faculty of Health Sciences,University of Macao,Macao 999078,China)

机构地区：[1]College of Veterinary Medicine,Shanxi Agricultural University,Jinzhong 030801,China [2]CAS Key Laboratory of Pathogen Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China [3]School of Life Sciences,Yunnan University,Kunming 650091,China [4]School of Life Sciences,Peking University,Beijing 100871,China [5]State Key Laboratory of Microbial Resources,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China [6]Faculty of Health Sciences,University of Macao,Macao 999078,China

出　　处：《Science Bulletin》2023年第23期3003-3012,M0005,共11页科学通报（英文版）

基　　金：supported by the National Key R&D Program of China(2022YFC2303403);the National Natural Science Foundation of China(82225021 and 32171428);the CAS Young Scientists in Basic Research(YSBR-010)。

摘　　要：新冠病毒(SARS-CoV-2)的不断进化带来了大量的变异株,特别是Omicron变异株及其众多的亚型.这些变异株表现出越来越强的免疫逃逸能力,使现有疫苗和治疗抗体的效力不断下降.目前,众多变异株已表现出血清交叉中和作用减弱的现象,表明新冠病毒可能已进化出多种血清型.因此,我们选取新冠病毒的主要抗原,即刺突(S)蛋白的受体结合域(RBD)对其进行血清分型.我们首先选择了23个具有代表性的新冠病毒毒株,涵盖了前Omicron变异株和Omicron变异株的多种亚型.通过对RBD抗原性的系统评估,我们将23种变异株分为5种血清型,每种血清型都包含了数种基因型不同的变异株.具体而言,Ⅰ型涵盖了所有前Omicron变异株(含两种亚型),而其余四种血清型均包含处于不同进化阶段的Omicron亚型.本文中的血清分型可以为新型变异株的快速评估奠定基础,并指导未来针对新冠病毒的广谱疫苗和中和抗体的开发.The continuous evolution of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has resulted in a significant number of variants,particularly with the emergence of Omicron with many sub-variants.These variants have exhibited increased immune escape,leading to reduced efficacy of existing vaccines and therapeutic antibodies.Given the diminished cross-neutralization observed among these variants,it is plausible that SARS-CoV-2 has developed multiple serotypes.As the major antigenic site,the receptorbinding domain(RBD)of viral spike(S)protein was chosen for serotyping.We selected 23 representative variants,including pre-Omicron variants and Omicron sub-variants,and classified them into five serotypes based on systematic evaluation of the antigenicities of their RBDs.Each serotype includes several genetically distinct variants.Serotype-I encompasses all pre-Omicron variants(with two subtypes),while the remaining four serotypes are all comprised of Omicron sub-variants at different stages of evolution.We propose that these serotypes can serve as a foundation for rapid classification of newly emerging SARS-CoV-2 variants,and guide the development of future broad-spectrum vaccines and neutralizing antibodies against the coronavirus disease 2019(COVID-19).

关 键 词：SARS-CoV-2 Serotype classification mRNA vaccine Spike(S) Receptor-binding domain(RBD) 

分 类 号：R373[医药卫生—病原生物学]